What is Pulse Biosciences Debt-to-Equity?
Pulse Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.06 Mil. Pulse Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $8.09 Mil. Pulse Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $44.36 Mil.
Pulse Biosciences's debt to equity for the quarter that ended in Dec. 2023 was 0.21.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Pulse Biosciences's Debt-to-Equity or its related term are showing as below:
PLSE'
s Debt-to-Equity Range Over the Past 10 Years
Min: -33.79 Med: 0.22 Max: 0.5
Current: 0.21
During the past 10 years, the highest Debt-to-Equity Ratio of Pulse Biosciences was 0.50. The lowest was -33.79. And the median was 0.22.
Pulse Biosciences Debt-to-Equity Historical Data
The historical data trend for Pulse Biosciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulse Biosciences Debt-to-Equity Chart
|
Pulse Biosciences Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
0.22 |
0.50 |
0.32 |
-33.79 |
0.21 |
|
Pulse Biosciences Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
-33.79 |
-7.09 |
0.16 |
0.18 |
0.21 |
Competitive Comparison of Pulse Biosciences's Debt-to-Equity
For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulse Biosciences's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Pulse Biosciences's Debt-to-Equity falls into.
Pulse Biosciences Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Pulse Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Pulse Biosciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulse Biosciences (Pulse Biosciences) Business Description
Traded in Other Exchanges
Address
3957 Point Eden Way, Hayward, CA, USA, 94545
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
Executives
| Robert W Duggan |
director, 10 percent owner |
611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756 |
| Kevin Patrick Danahy |
officer: Chief Commercial Officer |
50 TEABERRY LANE, BRAINTREE MA 02184 |
| Mitchell E. Levinson |
director |
3957 POINT EDEN WAY, HAYWARD CA 94545 |
| Manmeet Singh Soni |
director |
C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085 |
| Van Den Broek Richard |
director |
73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830 |
| Maky Zanganeh |
director |
51 ADAM WAY, ATHERTON CA 94027 |
| Sandra A. Gardiner |
officer: CFO & EVP Admin. and Finance |
CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
| Shelley D Spray |
director |
C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD CA 94545 |
| Laureen Debuono |
director |
|
| Ed Ebbers |
officer: EVP & GM, Dermatology |
3957 POINT EDEN WAY, HAYWARD CA 94545 |
| Kenneth A Clark |
director |
C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085 |
| Fogarty Thomas J M D |
director |
C/O VENTURE LAW GROUP, 2800 SAND HILL RD STE 270, MENLO PARK CA 94025 |
| Thierry B. Thaure |
director |
3957 POINT EDEN WAY, HAYWARD CA 94545 |
| Robert J. Greenberg |
director |
12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342 |
| Brian B Dow |
officer: CFO & SVP Admin. and Finance |
5675 GIBRALTAR AVENUE, PLEASANTON CA 94588 |
Pulse Biosciences (Pulse Biosciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PLSE has been successfully added to your